While PD-L1 expression levels do not precisely correspond to tumor therapeutic responses, the levels of this key immune checkpoint-related protein are nonetheless invaluable as a predictive biomarker associated with patient outcomes following immunotherapy (Jiang et al., 2019; Doroshow et al., 2021). Here, CD274 is linked to neoplasm.